12/23
09:17 am
ions
Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%? [Yahoo! Finance]
Low
Report
Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%? [Yahoo! Finance]
12/23
08:45 am
ions
PANTHERx® Rare Selected by Ionis as Specialty Pharmacy for TRYNGOLZA™ (olezarsen) [Yahoo! Finance]
Low
Report
PANTHERx® Rare Selected by Ionis as Specialty Pharmacy for TRYNGOLZA™ (olezarsen) [Yahoo! Finance]
12/20
08:19 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
12/20
08:06 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.
12/20
07:35 am
ions
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood [Yahoo! Finance]
Low
Report
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood [Yahoo! Finance]
12/19
06:45 pm
ions
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet [Yahoo! Finance]
Low
Report
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet [Yahoo! Finance]
12/19
06:28 pm
ions
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
Low
Report
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
12/16
08:50 am
ions
Muscular Dystrophy Association Announces Over $5 Million in Research Grants to Advance Neuromuscular Disease Research [Yahoo! Finance]
Low
Report
Muscular Dystrophy Association Announces Over $5 Million in Research Grants to Advance Neuromuscular Disease Research [Yahoo! Finance]
12/11
11:22 am
ions
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% [Yahoo! Finance]
Low
Report
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% [Yahoo! Finance]
12/8
06:10 am
ions
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
Low
Report
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
12/4
08:12 am
ions
Flamingo Therapeutics Announces Poster Presentation on AML Phase 1 IIT Study at ASH 2024 [Yahoo! Finance]
Medium
Report
Flamingo Therapeutics Announces Poster Presentation on AML Phase 1 IIT Study at ASH 2024 [Yahoo! Finance]
12/4
07:38 am
ions
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada [Yahoo! Finance]
Medium
Report
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada [Yahoo! Finance]
11/27
01:17 pm
ions
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
11/21
04:17 am
ions
Lou Gehrig's Disease Pipeline Landscape Report 2024: Therapeutic Assessment of 80+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Medium
Report
Lou Gehrig's Disease Pipeline Landscape Report 2024: Therapeutic Assessment of 80+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
11/18
11:38 am
ions
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks [Yahoo! Finance]
Low
Report
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks [Yahoo! Finance]
11/18
03:10 am
ions
ExeVir Announces Michael Garrett as New Chief Executive Officer [Yahoo! Finance]
Low
Report
ExeVir Announces Michael Garrett as New Chief Executive Officer [Yahoo! Finance]
11/14
10:12 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.
11/14
08:22 am
ions
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer [Yahoo! Finance]
Low
Report
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer [Yahoo! Finance]
11/12
02:01 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/7
11:47 am
ions
Company News for Nov 7, 2024 [Yahoo! Finance]
Low
Report
Company News for Nov 7, 2024 [Yahoo! Finance]
11/7
10:39 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an "overweight" rating on the stock.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an "overweight" rating on the stock.
11/7
08:36 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Medium
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
11/7
07:05 am
ions
Ionis to present at upcoming investor conferences
Low
Report
Ionis to present at upcoming investor conferences
11/7
02:31 am
ions
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... [Yahoo! Finance]
11/6
11:24 am
ions
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
Medium
Report
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]